MRI Assessment of Impaired Glucose Metabolism in Alzheimer's Disease

University of Aarhus

Status: Completed

Conditions: Alzheimer Disease

Treatments: Diagnostic Test: Deuterium metabolic imaging

Study type: Observational

Funder types: Other

Identifiers

NCT05402566

DMI-AD

Details and patient eligibility

About

Diseases of dementia are chronic, untreatable, and cause a massive burden of morbidity. In this proposal, we seek to tackle the problem of better, earlier, and more efficient diagnosis using deuterium metabolic imaging (DMI). The study is divided in two sub-studies: 1) optimization and simplification of DMI protocols, and 2) a cross-sectional study of DMI in Alzheimer's patients and healthy controls.

Enrollment: 21 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

AD-patients:

• Aged 55-85 years.
• Male or female.
• AD diagnosis by the NIA-AA 2011 research criteria.8
• Able to give written informed consent.
• Mini-mental state examination (MMSE) equal to or above 18.9
• Brain FDG-PET performed at Aarhus University Hospital consistent with AD.

Healthy participants:

• Aged 18-85 years.
• Male or female.

Exclusion criteria

All participants:

• Diabetes or any other metabolic disease.

• Other significant brain disease:

  • Strokes.
  • Tumors.
  • Chronic small vessel disease (clinically suspected, or Fazekas ≥ 2 if clinical MRI is available).
  • Epilepsy.
  • Other neurodegenerative or -inflammatory disease.

• Contraindications for MRI:

  • Pacemaker, neurostimulator or cochlear implant.
  • Metal foreign bodies such as fragments and irremovable piercings.
  • Unsafe medical implants (safety of heart valves, hips and the like must be confirmed).
  • Claustrophobia.
  • Largest circumference including arms > 160 cm.

• Pregnant - women must be post-menopausal or confirmed non-pregnant by an onsite test.

Trial design

21 participants in 3 patient groups

Healhy volunteers

Description:

Repeated MRI and DMI for simplification of protocols. Repeated within 6 +/- 2 weeks.

Treatment:

Diagnostic Test: Deuterium metabolic imaging

Alzheimer's disease patients

Description:

MRI and DMI to assess cerebral glucose metabolism. Single examination. Compared with PET.

Treatment:

Diagnostic Test: Deuterium metabolic imaging

Healthy controls

Description:

MRI and DMI for comparison with AD patients.

Treatment:

Diagnostic Test: Deuterium metabolic imaging